vs
Apellis Pharmaceuticals, Inc.（APLS）与Piedmont Realty Trust, Inc.（PDM）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Piedmont Realty Trust, Inc.的1.4倍（$199.9M vs $143.3M），Apellis Pharmaceuticals, Inc.净利率更高（-29.5% vs -31.4%，领先1.9%），Piedmont Realty Trust, Inc.同比增速更快（0.4% vs -5.9%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 0.0%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Piedmont Realty Trust是一家公开上市的房地产投资信托（REIT），主要持有、运营和投资美国高增长大都会区的优质写字楼资产，服务科技、专业服务、医疗等多个行业的企业租户，通过战略资产管理和投资组合优化为利益相关方提供稳定长期回报。
APLS vs PDM — 直观对比
营收规模更大
APLS
是对方的1.4倍
$143.3M
营收增速更快
PDM
高出6.4%
-5.9%
净利率更高
APLS
高出1.9%
-31.4%
两年增速更快
APLS
近两年复合增速
0.0%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $143.3M |
| 净利润 | $-59.0M | $-45.0M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | — |
| 净利率 | -29.5% | -31.4% |
| 营收同比 | -5.9% | 0.4% |
| 净利润同比 | -62.2% | -27.9% |
| 每股收益（稀释后） | $-0.40 | $-0.10 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSPDM
| Q1 26 | — | $143.3M | ||
| Q4 25 | $199.9M | $142.9M | ||
| Q3 25 | $458.6M | $139.2M | ||
| Q2 25 | $178.5M | $140.3M | ||
| Q1 25 | $166.8M | $142.7M | ||
| Q4 24 | $212.5M | $143.2M | ||
| Q3 24 | $196.8M | $139.3M | ||
| Q2 24 | $199.7M | $143.3M |
净利润APLSPDM
| Q1 26 | — | $-45.0M | ||
| Q4 25 | $-59.0M | $-43.2M | ||
| Q3 25 | $215.7M | $-13.5M | ||
| Q2 25 | $-42.2M | $-16.8M | ||
| Q1 25 | $-92.2M | $-10.1M | ||
| Q4 24 | $-36.4M | $-30.0M | ||
| Q3 24 | $-57.4M | $-11.5M | ||
| Q2 24 | $-37.7M | $-9.8M |
营业利润率APLSPDM
| Q1 26 | — | — | ||
| Q4 25 | -25.6% | — | ||
| Q3 25 | 48.7% | — | ||
| Q2 25 | -18.6% | — | ||
| Q1 25 | -50.0% | — | ||
| Q4 24 | -12.3% | — | ||
| Q3 24 | -24.0% | — | ||
| Q2 24 | -14.7% | — |
净利率APLSPDM
| Q1 26 | — | -31.4% | ||
| Q4 25 | -29.5% | -30.3% | ||
| Q3 25 | 47.0% | -9.7% | ||
| Q2 25 | -23.6% | -12.0% | ||
| Q1 25 | -55.3% | -7.1% | ||
| Q4 24 | -17.1% | -20.9% | ||
| Q3 24 | -29.2% | -8.3% | ||
| Q2 24 | -18.9% | -6.8% |
每股收益（稀释后）APLSPDM
| Q1 26 | — | $-0.10 | ||
| Q4 25 | $-0.40 | $-0.34 | ||
| Q3 25 | $1.67 | $-0.11 | ||
| Q2 25 | $-0.33 | $-0.14 | ||
| Q1 25 | $-0.74 | $-0.08 | ||
| Q4 24 | $-0.30 | $-0.25 | ||
| Q3 24 | $-0.46 | $-0.09 | ||
| Q2 24 | $-0.30 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $2.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $1.5B |
| 总资产 | $1.1B | $4.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSPDM
| Q1 26 | — | $2.3M | ||
| Q4 25 | $466.2M | $731.0K | ||
| Q3 25 | $479.2M | $3.0M | ||
| Q2 25 | $370.0M | $3.3M | ||
| Q1 25 | $358.4M | $2.9M | ||
| Q4 24 | $411.3M | $109.6M | ||
| Q3 24 | $396.9M | $133.6M | ||
| Q2 24 | $360.1M | $138.5M |
总债务APLSPDM
| Q1 26 | — | — | ||
| Q4 25 | — | $2.2B | ||
| Q3 25 | — | $2.2B | ||
| Q2 25 | — | $2.2B | ||
| Q1 25 | — | $2.2B | ||
| Q4 24 | — | $2.2B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B |
股东权益APLSPDM
| Q1 26 | — | $1.5B | ||
| Q4 25 | $370.1M | $1.5B | ||
| Q3 25 | $401.2M | $1.5B | ||
| Q2 25 | $156.3M | $1.5B | ||
| Q1 25 | $164.2M | $1.6B | ||
| Q4 24 | $228.5M | $1.6B | ||
| Q3 24 | $237.1M | $1.6B | ||
| Q2 24 | $264.3M | $1.7B |
总资产APLSPDM
| Q1 26 | — | $4.0B | ||
| Q4 25 | $1.1B | $4.0B | ||
| Q3 25 | $1.1B | $4.0B | ||
| Q2 25 | $821.4M | $4.0B | ||
| Q1 25 | $807.3M | $4.0B | ||
| Q4 24 | $885.1M | $4.1B | ||
| Q3 24 | $901.9M | $4.1B | ||
| Q2 24 | $904.5M | $4.2B |
负债/权益比APLSPDM
| Q1 26 | — | — | ||
| Q4 25 | — | 1.49× | ||
| Q3 25 | — | 1.43× | ||
| Q2 25 | — | 1.41× | ||
| Q1 25 | — | 1.40× | ||
| Q4 24 | — | 1.40× | ||
| Q3 24 | — | 1.36× | ||
| Q2 24 | — | 1.34× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | 110.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSPDM
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $140.6M | ||
| Q3 25 | $108.5M | $35.8M | ||
| Q2 25 | $4.4M | $50.1M | ||
| Q1 25 | $-53.4M | $3.7M | ||
| Q4 24 | $19.4M | $198.1M | ||
| Q3 24 | $34.1M | $42.9M | ||
| Q2 24 | $-8.3M | $66.8M |
自由现金流APLSPDM
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-8.4M | — |
自由现金流率APLSPDM
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.2% | — |
资本支出强度APLSPDM
| Q1 26 | — | 110.3% | ||
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — |
现金转化率APLSPDM
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
PDM
暂无分部数据
